The RheumNow Week in Review – Modifiable Behavior (5.18.18) Save
Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com. He discusses opioids, new approval for polyarticular JIA, running and osteoarthritis and modifiable behaviors that influence outcomes.
- Osteoarthritis Initiative study of 1203 pts shows that running was not associated with worsening of knee pain or radiographic structural progression https://t.co/Y7UCTNMpKy
- Genentech announces that the FDA has approved Actemra for use in Active Polyarticular Juvenile Idiopathic Arthritis. https://t.co/E4z3K5LeBQ
- RA pts have a greater risk of CVA; Study of 7904 RA pts shows that short-term (https://t.co/gRM9yrJOS0 RA 21% ^risk.
- Walmart (Sams) announced it is following CDC opioid prescribing recs and will soon limit initial opioid prescriptions to no more than seven days of supply, aiming avoid abuse https://t.co/uzn2xhbYL7
- UAB to lead the RECIPE trial in gout - a phase II trial to evaluate the utility of background mycophenolate (MMF) in patient receiving IV pegloticase injection for gout. Presumeably the MMF will block any interferring immunogenicity to PEG. https://t.co/ypBjwkeLpf
- Study of 148 SLE women shows obesity to be independently associated with worse disease activity, depressive symptoms, and symptoms of pain and fatigue. Obesity may be a modifiable target in SLE. https://t.co/XtrYr49msZ
- Lupus and diabetes have similar CVD risk; Claims data study of Medicaid pts shows SLE pts receive less lipids testing (66% less) & less likely to fill a statin Rx (82% less than DM; 11% less than Nl Pop) https://t.co/cjo4AtXHQs
- Opioid Marketing & Meals Tied to Opioid Prescribing
- Ankylosing Spondylitis Women Show Less Durable Responses to TNF Inhibitors
The author has received compensation as an advisor or consultant on this subject